Literature DB >> 8098789

Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes.

L C Harrison1, M C Honeyman, H J DeAizpurua, R S Schmidli, P G Colman, B D Tait, D S Cram.   

Abstract

Glutamic acid decarboxylase (GAD) in pancreatic beta cells is an autoantigen in insulin-dependent diabetes (IDD). We measured immunity to GAD in 31 first-degree relatives of IDD patients judged to be at risk of developing IDD themselves because of the presence of islet-cell antibodies. We found that in most of the subjects GAD autoimmunity was either predominantly humoral or predominantly cellular. High concentrations of circulating autoantibodies that precipitate native GAD activity were associated with low proliferation of peripheral-blood T cells to recombinant GAD; conversely, low concentrations of autoantibody to GAD were associated with high T-cell proliferation to GAD. Although T-cell proliferation was measured in the presence of autologous serum, GAD autoantibodies did not have a blocking effect in vitro. This dichotomy of the immune response to GAD defined heterogeneity within at-risk relatives and could have prognostic importance. We postulate that, if GAD is a pathogenetic autoantigen, sensitisation to beta-cell GAD is more likely to lead to IDD when the immune response deviates towards the expansion of autoreactive T cells rather than towards generation of autoantibodies. This idea is consistent with evidence that beta-cell destruction is mediated by T cells and that high concentrations of GAD antibodies are associated with slower progression to clinical disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098789     DOI: 10.1016/0140-6736(93)90940-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

Review 1.  T-cell reactivity to beta-cell antigens in human insulin-dependent (type 1) diabetes mellitus. Implications for diagnosis and therapy.

Authors:  B O Roep
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

3.  Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.

Authors:  S D Patel; A P Cope; M Congia; T T Chen; E Kim; L Fugger; D Wherrett; G Sonderstrup-McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

5.  The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.

Authors:  Stef J Bloem; Bart O Roep
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

6.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.

Authors:  W A Hagopian; C B Sanjeevi; I Kockum; M Landin-Olsson; A E Karlsen; G Sundkvist; G Dahlquist; J Palmer; A Lernmark
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes.

Authors:  M A Atkinson; M A Bowman; L Campbell; B L Darrow; D L Kaufman; N K Maclaren
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 9.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

10.  T lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes.

Authors:  R Kotani; M Nagata; A Imagawa; H Moriyama; H Yasuda; J Miyagawa; T Hanafusa; K Yokono
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.